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Abstract 
Brain metastases are a very frequent and life-limiting complication in cancer patients. 
Many aspects of brain metastasis pathobiology remain poorly understood and only 
very few clinical studies are available to guide patient management on a high level of 
evidence. However, in recent years, there is an increasing interest in brain 
metastasis research, partly motivated by increasing incidences of brain metastases 
that are associated with increasing survival times of cancer patients due to novel 
oncological therapeutics. Emerging studies are providing novel data on biological 
processes of brain metastasis formation and clinical investigations are focusing on 
specific questions in cohorts of patients with CNS metastases. It is expected that 
these activities will lead to improved understanding and clinical management 
strategies for patients with brain metastases. 
  
	 3
Text body 
Brain metastases are a very frequent and life-limiting complication in cancer patients 
and are associated with serious neurological and neurocognitive symptoms	(1). It is 
estimated that up to 30% of cancer patients develop brain metastases during their 
disease course, with lung cancer, breast cancer, melanoma and renal cell cancer 
carrying the highest risk of CNS spread. Paradoxically, despite the fact that brain 
metastases are a common and serious clinical problem in the everyday setting of 
clinical oncology, relatively little research has been conducted on this issue in the 
past decades. It is interesting to note that although gliomas are approximately 10-fold 
less common than brain metastases, the number of papers published on gliomas 
was around 4-times higher than the number of papers published on brain metastases 
in the time period 1967 to 2013 (Figure 1). Furthermore, the methodology of 
research on gliomas has in general been far more sophisticated, be it in basic, 
translational or clinical science. The glioma literature features plenty of papers 
describing advanced research projects utilizing animal models, molecular biological 
techniques, next-generation gene sequencing approaches, large multinational 
randomized clinical trials and other cutting edge methods. In contrast, many brain 
metastasis papers have major methodological limitations. Only few well established 
experimental models are available and unfortunately brain metastasis patients have 
been systematically excluded from most clinical trials of novel agents for patients with 
solid tumors. Most of the few available clinical trials on brain metastasis patients 
have included heterogeneous and small patient populations that limit the conclusions 
that can be drawn. Consequently, there is a lack of understanding many aspects of 
brain metastasis pathobiology and only very few adequately powered and well-
performed clinical studies are available to guide patient management on a high level 
of evidence. However, in the past few years, there is an increasing interest in brain 
metastasis research, partly motivated by increasing incidences of brain metastases 
that come along with increased survival times of cancer patients due to novel and 
effective oncological therapeutics. Emerging studies are providing novel knowledge 
on biological processes of brain metastasis formation and clinical investigations are 
focusing on specific questions in cohorts of patients with CNS metastases	(2, 3). It is 
expected that these activities will lead to improved understanding and clinical 
management strategies. 
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In this Special Issue of Chinese Clinical Oncology, international experts will in a 
series of articles provide an overview of the current state and emerging perspectives 
on various aspects of brain metastasis research. The topics covered include 
neuroimaging, prognostic scoring systems, neurosurgical and radiosurgical decision 
making, strategies for preservation of memory function, the inflammatory 
microenvironment, genomic profiling, novel targeted agents and the management of 
leptomenigial carcinomatosis in cancer patients with CNS affection. It is clear that the 
field of brain metastasis research is finally developing a considerable drive and 
significant advances are being made in preclinical, translational and clinical science 
that start to translate into better treatments and improved outcomes of brain 
metastasis patients. 
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Legend to Figure 1: Number of articles published on glioma and on brain 
metastases in the perios 1967 to 2013 (Source: www.pubmed.gov). 
 
 
